Cognivia has announced the launch of its latest solution: Compl-AI©™.
Compl-AI is a predictive tool that helps clinical trial sponsors with patient recruitment and engagement strategies. The new tool scores patient behavior at screening using machine learning. The Compl-AI patient behavior score enables individualized patient engagement strategies. Beyond clinical research, Compl-AI offers healthcare providers an approach to tailor and adjust their patient support for better treatment adherence.
Using Compl-AI, sponsors can detect the risk of non-compliance and drop out risk before the start and monitor it over the course of their clinical trial.
Cognivia expands its portfolio of predictive solutions introducing Compl-AI©™, an innovative solution that predicts the risk of patient nonadherence & dropout. (2023, May 23). Cision PR Newswire.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.